

Mytesi (crofelemer)
Effective 02/20/19

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Mytesi is an anti-diarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.

Coverage Guidelines

Authorization may be granted when the following criteria are met:

1. Patient is ≥ 18 years of age **AND**
2. Patient has a diagnosis of human immunodeficiency virus (HIV) or acquired immunodeficiency disease (AIDS) and is actively receiving anti-retroviral therapy which has resulted in a non- infectious form of diarrhea **AND**
3. Patient has experienced an inadequate response or intolerance to treatment with both loperamide and diphenoxylate w/atropine.

Continuation of Therapy

1. Patient continues to actively receive anti-retroviral therapy **AND**
2. Symptom improvement per physician assessment

Limitations

1. Approvals will be granted for 12 months.

References

1. Mytesi (crofelemer) [prescribing information]. San Francisco, CA: Napo Pharmaceuticals Inc; June 2016



2. Feasey NA, Healey P, Gordon MA. Review article: the aetiology, investigation and management of diarrhea in the HIV -positive patient. *Aliment Pharmacol Ther.* 2011;34(6):587-603.
3. MacArthur RD, Hawkins TN, Brown SJ, LaMarca A, Clay PG, Barrett AC, et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT Trial): A randomized, double-blind, placebo-controlled, two- stage study. *HIV Clin Trials* 2013; 14(6):261-273.
4. US Food and Drug Administration. FDA News Release. FDA approves first anti-diarrheal drug for HIV/AIDS patients. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333701.htm>
5. Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy. Frampton JE. *Drugs.* 2013 Jul;73(10):1121-9. doi: 10.1007/s40265-013-0083-6. Review.

Review History

00/00/14 – Implemented
02/23/15 - Reviewed
02/22/16 - Reviewed
02/27/17 - Reviewed
02/26/18 – Updated (renamed Mytesi)
02/20/19 – Updated

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.